Company profile
EXELIXIS, INC.
NASDAQ:EXELBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (9)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| CABOMETYX | approved | — | 7 | approved |
| COMETRIQ | approved | — | 7 | approved |
| ZANZALINTINIB | phase3 | — | 14 | active |
| CASDATIFAN | phase1 | — | 1 | terminated |
| PILARALISIB | phase1 | — | 13 | completed, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (56)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06630247 | phase1 | terminated | 2024-10-17 | 2025-05-07 | Exelixis | A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors |
| NCT01100619 | phase1 | completed | 2010-04-01 | 2012-08-01 | Exelixis | A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors |
| NCT00595829 | phase1 | terminated | 2007-12-01 | 2009-02-01 | Exelixis | A Phase 1 Study of XL019 in Adults With Polycythemia Vera |
| NCT05932862 | phase1 | recruiting | 2024-04-03 | 2029-01-03 | Exelixis | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors |
| NCT00570635 | phase2 | completed | 2007-12-01 | 2009-05-01 | Exelixis | A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib |
FDA applications (2)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 208692 | 2016-04-25 | NDA | EXELIXIS INC | |||||
Loading… | ||||||||
| NDA 203756 | 2012-11-29 | NDA | EXELIXIS INC | |||||
Loading… | ||||||||